Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Anticancer Research
|
January 31, 2012
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy
Frank Richardson, G David Young, Regina Sennello, et al.
Molecular and Cellular Biology
|
November 6, 2019
Function of the MYND Domain and C-Terminal Region in Regulating the Subcellular Localization and Catalytic Activity of the SMYD Family Lysine Methyltransferase Set5
Deepika Jaiswal, Rashi Turniansky, James J Moresco, et al.
Cancer Chemotherapy and Pharmacology
|
December 7, 2006
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
Tomislav Dragovich, Mark Huberman, Daniel D Von Hoff, et al.
Mbio
|
February 14, 2018
The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles
Louise Walker, Prashant Sood, Megan D Lenardon, et al.
The Oncologist
|
November 22, 2017
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
Eileen M O'Reilly, James Roach, Paul Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2009
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers
Andrew N Hughes, Mary E R O'Brien, W Jeffrey Petty, et al.
Cerebral Cortex (New York, N.Y. : 1991)
|
May 22, 2025
Brain-wide connectivity changes due to social-emotional regulation during a naturalistic fMRI task
Christopher J Hyatt, Bruce E Wexler, Gretchen J Diefenbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2006
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
Amita Patnaik, Debra Wood, Anthony W Tolcher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2020
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
Eileen M O'Reilly, Diletta Barone, Devalingam Mahalingam, et al.
Journal of Feline Medicine and Surgery
|
February 22, 2018
Effectiveness of GonaCon as an immunocontraceptive in colony-housed cats
Amy Fischer, Valerie Aw Benka, Joyce R Briggs, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Anticancer Research
|
January 31, 2012
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy
Frank Richardson, G David Young, Regina Sennello, et al.
Molecular and Cellular Biology
|
November 6, 2019
Function of the MYND Domain and C-Terminal Region in Regulating the Subcellular Localization and Catalytic Activity of the SMYD Family Lysine Methyltransferase Set5
Deepika Jaiswal, Rashi Turniansky, James J Moresco, et al.
Cancer Chemotherapy and Pharmacology
|
December 7, 2006
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
Tomislav Dragovich, Mark Huberman, Daniel D Von Hoff, et al.
Mbio
|
February 14, 2018
The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles
Louise Walker, Prashant Sood, Megan D Lenardon, et al.
The Oncologist
|
November 22, 2017
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
Eileen M O'Reilly, James Roach, Paul Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2009
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers
Andrew N Hughes, Mary E R O'Brien, W Jeffrey Petty, et al.
Cerebral Cortex (New York, N.Y. : 1991)
|
May 22, 2025
Brain-wide connectivity changes due to social-emotional regulation during a naturalistic fMRI task
Christopher J Hyatt, Bruce E Wexler, Gretchen J Diefenbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2006
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
Amita Patnaik, Debra Wood, Anthony W Tolcher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2020
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
Eileen M O'Reilly, Diletta Barone, Devalingam Mahalingam, et al.
Journal of Feline Medicine and Surgery
|
February 22, 2018
Effectiveness of GonaCon as an immunocontraceptive in colony-housed cats
Amy Fischer, Valerie Aw Benka, Joyce R Briggs, et al.
Page
of 4